Form 4: Verve Therapeutics Completes Acquisition by Eli Lilly, Shareholders Receive Cash and CVRs

Verve Therapeutics, Inc. has finalized its merger with Eli Lilly and Company, with shareholders receiving $10.50 per share in cash plus a contingent value right for potential additional payments.

Summary

• Verve Therapeutics, Inc. has completed its merger with Eli Lilly and Company, with Verve becoming a wholly-owned subsidiary of Eli Lilly.
• The merger was effective as of July 25, 2025, following a tender offer by Eli Lilly's subsidiary, Ridgeway Acquisition Corporation.
• Shareholders of Verve Therapeutics received $10.50 per share in cash (Cash Consideration) for each share tendered.
• In addition to the cash, shareholders also received one non-tradable Contingent Value Right (CVR) per share, which offers a contractual right to receive up to $3.00 per CVR upon the achievement of a specified business milestone.
• Outstanding stock options with an exercise price less than the Cash Consideration were automatically cancelled at the effective time of the merger.
• Holders of these 'Cash-Out Stock Options' received a cash payment equal to the difference between the Cash Consideration and the option's exercise price, multiplied by the number of shares underlying the option.
• Option holders also received one CVR for each share subject to their Cash-Out Stock Option.
• Following the reported transactions, Burt A Adelman, a Director of Verve Therapeutics, beneficially owns 0 shares of Common Stock and 0 Stock Options, indicating the completion of the transaction for his holdings.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for former Verve Therapeutics shareholders as the company was acquired at a premium, providing immediate cash value and potential future upside through CVRs. The transaction successfully closed as planned.

Positives

• Shareholders received a fixed cash payment of $10.50 per share, providing immediate liquidity and a defined return.
• The inclusion of a Contingent Value Right (CVR) offers potential additional upside of up to $3.00 per CVR if a specific business milestone is achieved, allowing shareholders to participate in future success.
• Stock option holders with in-the-money options received cash for the intrinsic value of their options plus CVRs, ensuring they benefited from the acquisition.

Negatives

• Verve Therapeutics, Inc. is no longer an independent publicly traded entity, becoming a wholly-owned subsidiary of Eli Lilly and Company.
• The CVR is non-tradable, limiting liquidity for this portion of the consideration.
• The achievement of the CVR milestone is contingent, meaning the additional $3.00 payment is not guaranteed.

Risks

• The Contingent Value Right (CVR) payment of up to $3.00 is contingent upon the achievement of a specific milestone, and there is no guarantee that this milestone will be met, meaning the full potential value may not be realized.
• The CVRs are non-tradable, limiting the ability of holders to sell or transfer their rights before the milestone is determined.

Future Outlook

The future outlook for former Verve Therapeutics shareholders includes the potential to receive an additional payment of up to $3.00 per CVR, contingent upon the achievement of a specific business milestone related to Verve's business. Verve Therapeutics will continue its operations as a wholly-owned subsidiary of Eli Lilly and Company.

Industry Context

This acquisition reflects the ongoing trend of consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies like Eli Lilly acquire innovative smaller biotechs to expand their pipelines and capabilities. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks and rewards, particularly for assets in clinical development.

Comparison to Industry Standards

• The use of a CVR in this acquisition aligns with common practices in the biotechnology and pharmaceutical industry for deals involving clinical-stage assets, where future success is uncertain. This mechanism allows the acquirer to mitigate risk while providing potential upside to the target's shareholders.
• The structure of the deal, combining an upfront cash payment with a contingent component, is comparable to other recent biotech acquisitions where the target company possesses promising but unproven therapeutic candidates.

Stakeholder Impact

• Shareholders: Received cash consideration and CVRs for their shares, realizing value from their investment. The company is no longer publicly traded.
• Employees: Verve Therapeutics continues as a wholly-owned subsidiary, implying continuity for employees under Eli Lilly's ownership.
• Management: The reporting person, a director, no longer holds shares or options in the now-acquired entity, indicating the completion of their financial interest in the independent company.

Next Steps

• Achievement of the specified milestone for the Contingent Value Right (CVR) payment.
• Integration of Verve Therapeutics' operations and pipeline into Eli Lilly and Company.

Key Dates

Keywords

Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Eli Lilly, Verve Therapeutics, Biotechnology, Pharmaceuticals, SEC Form 4, Stock Options, Corporate Action